Clinical Trial

A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 18, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 2 study to evaluate the efficacy,and safety of TQB2102 for injection in recurrent/metastatic advanced gynecological tumors.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-01-23; most recent amendment 2025-07-16.
Status change: Not Yet Recruiting → Recruiting 2025-03-18
Trial Details
NCT Number NCT06798207
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Gynecological Tumors
Enrollment 170 participants
Start Date 2025-03-13
Primary Completion 2026-05 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-07-18